tolafentrine has been researched along with Pulmonary Hypertension in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fleming, I; Ghofrani, HA; Grimminger, F; Leiper, J; Mayer, K; Pullamsetti, SS; Savai, R; Schaefer, MB; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N; Wilhelm, J | 1 |
| Talukder, MA; Zweier, JL | 1 |
| Ghofrani, HA; Grimminger, F; Olschewski, H; Rose, F; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Weissmann, N; Wiedemann, R | 1 |
| Ermert, L; Ghofrani, HA; Grimminger, F; Kreisselmeier, KP; Pullamsetti, S; Samidurai, A; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N | 1 |
| Fuchs, B; Ghofrani, HA; Grimminger, F; Krick, S; Pullamsetti, S; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N; Yilmaz, H | 1 |
| Enke, B; Ghofrani, HA; Grimminger, F; Schermuly, RT; Schudt, C; Seeger, W; Walmrath, D; Weissmann, N | 1 |
| Ghofrani, HA; Grimminger, F; Roehl, A; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Walmrath, D; Weissmann, N | 1 |
| Ghofrani, HA; Grimminger, F; Krupnik, E; Rose, F; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Walmrath, D; Weissmann, N | 1 |
1 trial(s) available for tolafentrine and Pulmonary Hypertension
| Article | Year |
|---|---|
Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension.
Topics: Adult; Aerosols; Aged; Area Under Curve; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Naphthyridines; Phosphodiesterase Inhibitors; Statistics, Nonparametric; Vascular Resistance; Vasodilation; Vasodilator Agents | 2002 |
7 other study(ies) available for tolafentrine and Pulmonary Hypertension
| Article | Year |
|---|---|
cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Amidohydrolases; Apoptosis; Arginine; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclic GMP; Cytokines; Endothelial Cells; Hemodynamics; Humans; Hypertension, Pulmonary; Naphthyridines; Nitric Oxide; Phosphodiesterase Inhibitors; Promoter Regions, Genetic; Pulmonary Gas Exchange | 2011 |
Targeting dimethylarginine dimethylaminohydrolases in pulmonary arterial hypertension: a new approach to improve vascular dysfunction?
Topics: Amidohydrolases; Arginine; Humans; Hypertension, Pulmonary; Naphthyridines; Nitric Oxide; Nitric Oxide Synthase; Phosphodiesterase Inhibitors | 2011 |
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gelatinases; Hemodynamics; Hypertension, Pulmonary; Hypertrophy; Hypertrophy, Right Ventricular; Iloprost; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocrotaline; Muscle, Smooth, Vascular; Naphthyridines; Oxygen; Phosphodiesterase Inhibitors; Pulmonary Artery; Pulmonary Gas Exchange; Pulmonary Heart Disease; Rats; Rats, Sprague-Dawley; Vasodilator Agents; Ventricular Remodeling | 2004 |
Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
Topics: Administration, Inhalation; Animals; Cell Movement; Dose-Response Relationship, Drug; Extracellular Matrix; Hypertension, Pulmonary; Male; Monocrotaline; Myocytes, Smooth Muscle; Naphthyridines; Rats | 2005 |
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Aerosols; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Hypertension, Pulmonary; Naphthyridines; Phosphodiesterase Inhibitors; Pulmonary Circulation; Purinones; Pyridazines; Rabbits; Rolipram; Vasoconstrictor Agents; Vasodilation | 1999 |
Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Antihypertensive Agents; Cyclic AMP; Dose-Response Relationship, Drug; Drug Interactions; Edema; Epoprostenol; Female; Hemodynamics; Hypertension, Pulmonary; Lung; Male; Naphthyridines; Perfusion; Phosphodiesterase Inhibitors; Pyridazines; Rabbits; Rolipram; Time Factors; Vasoconstrictor Agents | 2000 |
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemodynamics; Hypertension, Pulmonary; Iloprost; Naphthyridines; Pentoxifylline; Phosphodiesterase Inhibitors; Rabbits; Vasodilation; Vasodilator Agents | 2001 |